Log in
Enquire now
‌

US Patent 10407501 Humanized or chimeric CD3 antibodies

Patent 10407501 was granted and assigned to Genmab A/S on September, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
‌
Genmab A/S
0
Date Filed
January 8, 2015
0
Date of Patent
September 10, 2019
0
Patent Applicant
‌
Genmab A/S
0
Patent Application Number
15110414
0
Patent Citations Received
‌
US Patent 11970544 Antibodies
0
‌
US Patent 11535679 Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
0
‌
US Patent 11548952 Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
0
‌
US Patent 11008399 Antibodies
0
‌
US Patent 11608383 Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
0
‌
US Patent 11261254 Antibodies
0
‌
US Patent 11359015 Humanized or chimeric CD3 antibodies
‌
US Patent 11858995 Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia
0
‌
US Patent 11485796 Inert format
0
Patent Inventor Names
Aran Frank Labrijn
0
Edward Norbert Van Den Brink
0
Isil Altintas
0
Joyce Meesters
0
Paul Parren
0
Rik Rademaker
0
Janine Schuurman
0
Joost J. Neijssen
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
10407501
0
Patent Primary Examiner
‌
Zachary S Skelding
0

Find more entities like US Patent 10407501 Humanized or chimeric CD3 antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.